Novo and existing backer GV participated in a round that lifted the heart disease drug developer's overall funding to more than $215m.

US-based cardiovascular disease drug developer Verve Therapeutics closed a $94m series B round yesterday featuring pharmaceutical firm Novo and GV, a corporate venturing subsidiary of internet and technology group Alphabet. Wellington Management and Casdin Capital co-led the round, which included Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Logos Capital, Surveyor Capital,…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.